| scholarly article | Q13442814 |
| P50 | author | Hamidreza Jamshidi | Q56840188 |
| P2093 | author name string | Hamid Reza Jamshidi | |
| Hamid Reza Rasekh | |||
| Mohsen Khatibi | |||
| Zohreh Shahverdi | |||
| P2860 | cites work | Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts | Q24645760 |
| Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
| Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q28294460 | ||
| The surveillance, epidemiology, and end results program: a national resource | Q33804988 | ||
| Cost-effectiveness of a potential vaccine for human papillomavirus | Q33865463 | ||
| Worldwide burden of cervical cancer in 2008. | Q34176394 | ||
| Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis | Q34318787 | ||
| Role of herd immunity in determining the effect of vaccines against sexually transmitted disease | Q34380787 | ||
| Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature | Q34497190 | ||
| Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? | Q35887504 | ||
| Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature | Q36309222 | ||
| Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease | Q36494809 | ||
| Chapter 2: The burden of HPV-related cancers | Q36584354 | ||
| Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling | Q36584372 | ||
| Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes | Q36584377 | ||
| Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party | Q36599584 | ||
| Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 | ||
| The economic burden of noncervical human papillomavirus disease in the United States | Q36740006 | ||
| Review of the economic and quality-of-life burden of cervical human papillomavirus disease | Q36754892 | ||
| Cost-effectiveness analyses of human papillomavirus vaccination | Q36765963 | ||
| Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing | Q36815006 | ||
| Human papillomavirus vaccination in males | Q36972163 | ||
| Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. | Q37274801 | ||
| Model for assessing human papillomavirus vaccination strategies | Q37302509 | ||
| Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 | ||
| Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests | Q44529186 | ||
| Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance | Q45305963 | ||
| The cost-effectiveness of male HPV vaccination in the United States | Q48617316 | ||
| Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. | Q50723929 | ||
| Diagnoses and outcomes in cervical cancer screening: a population-based study. | Q50747235 | ||
| Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. | Q51960934 | ||
| A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. | Q53173185 | ||
| Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine | Q57089428 | ||
| Genital human papillomavirus infection | Q64130358 | ||
| Toward consistency in cost-utility analyses: using national measures to create condition-specific values | Q74660492 | ||
| The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada | Q80462054 | ||
| P433 | issue | Suppl | |
| P921 | main subject | cost-effectiveness analysis | Q1754768 |
| Iran | Q794 | ||
| human papilloma virus | Q69999790 | ||
| P304 | page(s) | 225-234 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Iranian journal of pharmaceutical research | Q20183787 |
| P1476 | title | Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran | |
| P478 | volume | 13 |
| Q35484171 | Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran |
| Q57162663 | Cervical cancer in Iran: integrative insights of epidemiological analysis |
| Q30245295 | Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations |
| Q37246445 | Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran |
| Q36760082 | Priority Setting for Improvement of Cervical Cancer Prevention in Iran |
Search more.